Amgen Kineret Needs Enbrel Combo Study And Combo Use Warning - Cmte
Executive Summary
Labeling for Amgen's rheumatoid arthritis product Kineret (anakinra) should carry a strong warning against use with TNF-inhibitors, pending a double-blind safety trial studying combination use with Immunex' Enbrel (etanercept), FDA's Arthritis Advisory Committee recommended Aug. 16.
You may also be interested in...
Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.
Anti-TNF rheumatoid arthritis drug class labeling for tuberculosis risk was discussed by FDA's Arthritis Advisory Committee during an Aug. 17 safety update on Immunex' Enbrel (etanercept) and Centocor's Remicade (infliximab).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011